By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has signed definitive agreements to sell 8.1 million shares of its stock to certain investors at $0.17 apiece, which would raise $1.4 million for the beleaguered microRNA diagnostics firm.

Rosetta said that the transactions are expected to close on April 17. The proceeds of the offering will be used to fund operations and other general corporate purposes, including the repayment of debt.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.